These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 8513859

  • 1. Characterization of tumor cell heterogeneity of a murine leukemia cell line (L1210) in response to arabinosylcytosine: quantitation using a computerized image analysis system.
    Raymakers RA, Slocum HK, Minderman H, Malmberg M, Rustum YM.
    Exp Hematol; 1993 May; 21(5):602-7. PubMed ID: 8513859
    [Abstract] [Full Text] [Related]

  • 2. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ.
    Cancer Res; 1987 Jun 01; 47(11):3005-11. PubMed ID: 3471322
    [Abstract] [Full Text] [Related]

  • 3. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI, Powell W.
    Cancer Invest; 1987 Jun 01; 5(4):293-9. PubMed ID: 3664332
    [Abstract] [Full Text] [Related]

  • 4. Paradoxical effect of cytosine arabinoside on mouse leukemia cell line L1210 cells.
    Nakayama T, Sakamoto S, Sassa S, Suzuki S, Kudo H, Nagasawa H.
    Anticancer Res; 2005 Jun 01; 25(1A):157-60. PubMed ID: 15816533
    [Abstract] [Full Text] [Related]

  • 5. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
    Abe I, Saito S, Hori K, Suzuki M, Sato H.
    Cancer Res; 1982 Jul 01; 42(7):2846-51. PubMed ID: 7083175
    [Abstract] [Full Text] [Related]

  • 6. Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67).
    Grant S, Freemerman AJ, Birrer MJ, Martin HA, Turner AJ, Szabo E, Chelliah J, Jarvis WD.
    Cell Growth Differ; 1996 May 01; 7(5):603-13. PubMed ID: 8732670
    [Abstract] [Full Text] [Related]

  • 7. Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells.
    Roberts D, Peck C, Hilliard S, Wingo W.
    Cancer Res; 1979 Oct 01; 39(10):4048-54. PubMed ID: 476642
    [Abstract] [Full Text] [Related]

  • 8. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
    Plunkett W, Nowak B, Keating MJ.
    Cancer Treat Rep; 1987 May 01; 71(5):479-83. PubMed ID: 3567973
    [Abstract] [Full Text] [Related]

  • 9. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI, Biener R, Krailo M, Finklestein J, Ettinger L, Willoughby M, Siegel SE, Holcenberg JS.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [Abstract] [Full Text] [Related]

  • 10. Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells.
    Cadman E, Eiferman F.
    J Clin Invest; 1979 Sep 15; 64(3):788-97. PubMed ID: 288743
    [Abstract] [Full Text] [Related]

  • 11. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF, Huang P, Plunkett W, Gandhi V.
    Clin Cancer Res; 1996 Apr 15; 2(4):653-8. PubMed ID: 9816215
    [Abstract] [Full Text] [Related]

  • 12. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
    Boos J, Hohenlöchter B, Schulze-Westhoff P, Schiller M, Zimmermann M, Creutzig U, Ritter J, Jurgens H.
    Med Pediatr Oncol; 1996 Jun 15; 26(6):397-404. PubMed ID: 8614376
    [Abstract] [Full Text] [Related]

  • 13. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO, Plunkett W, Dixon DO.
    Cancer Res; 1985 Nov 15; 45(11 Pt 2):5952-7. PubMed ID: 4053067
    [Abstract] [Full Text] [Related]

  • 14. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
    Kees UR, Ford J, Dawson VM, Piall E, Aherne GW.
    Cancer Res; 1989 Jun 01; 49(11):3015-9. PubMed ID: 2720661
    [Abstract] [Full Text] [Related]

  • 15. Intracellular pharmacodynamics of ara-C and flowcytometric analysis of cell cycle progression in leukemia chemotherapy.
    Nakamura T, Takauji R, Kamiya K, Kawai Y, Iwasaki H, Tohyama K, Yamauchi T, Ueda T.
    Leukemia; 1997 Apr 01; 11 Suppl 3():548-51. PubMed ID: 9209453
    [Abstract] [Full Text] [Related]

  • 16. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K, Nayak R, Grant S.
    Cancer Res; 1984 Nov 01; 44(11):5029-37. PubMed ID: 6091869
    [Abstract] [Full Text] [Related]

  • 17. Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.
    Burke PJ, Karp JE, Vaughan WP.
    J Natl Cancer Inst; 1981 Sep 01; 67(3):529-38. PubMed ID: 6944525
    [Abstract] [Full Text] [Related]

  • 18. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 01; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 19. S1-phase cells of the leukemic cell cycle sensitive to 1-beta-D-arabinofuranosylcytosine at a high-dose level.
    Smets LA, Homan-Blok J.
    Cancer Res; 1985 Jul 01; 45(7):3113-7. PubMed ID: 4005848
    [Abstract] [Full Text] [Related]

  • 20. Effect of the interval between exposures to cytarabine on its cytotoxic action on HL-60 myeloid leukemic cells.
    Leclerc JM, Momparler RL.
    Cancer Treat Rep; 1984 Sep 01; 68(9):1143-8. PubMed ID: 6592037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.